Patient with lung metastases of malignant melanoma who have long-term survival in combination therapy BRAF and MEK inhibitors
MUDr. Ilona Procházková
Dermatovenerologická klinika 1. LF UK a VFN, Praha
Targeted treatment of BRAF and MEK inhibitors and targeted antibody treatment against immune response checkpoints showed a significant advance in the treatment of generalized malignant melanoma against previously used chemotherapy and radiotherapy. The results of the clinical studies confirmed a markedly higher response rate and an increase in overall survival in patients treated with both types of this medications.
melanoma, imunotherapy, BRAF inhibitor, MEK inhibitor
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...